Stratec Se

Stratec SE's capital structure is characterized by a debt-to-equity ratio of 0.56, indicating a moderate level of leverage. The company's liquidity position is reflected in a current ratio of 3.97, suggesting it has sufficient short-term assets to cover its liabilities. However, the company reported negative operating and free cash flows of -433,000 EUR and -5,172,000 EUR, respectively, which may signal potential liquidity constraints. Profitability metrics for Stratec SE show a return on equity of -0.001 and a return on assets of -0.0006, both of which are negative and below the typical performance of the Advanced Medical Equipment & Technology industry. The company's net income was -242,000 EUR, indicating a loss for the period. Gross profit of 64,220,000 EUR suggests that the company is able to maintain some level of margin, but this is not sufficient to offset other costs and result in a net profit. Stratec SE's revenue is derived from the development and sale of analyzer systems and automation solutions for in-vitro diagnostics and life science companies. The company's geographic exposure is primarily within Germany, and there is no detailed breakdown of revenue by segment or region in the provided data. This lack of segmentation makes it difficult to assess the company's exposure to different markets or product lines. The company's growth trajectory is not clearly defined in the provided data, as there are no specific revenue growth figures or outlooks for the current or next fiscal year. The capital expenditure of -16,230,000 EUR indicates that the company is investing in its operations, which could be a sign of expansion or modernization. However, the negative free cash flow suggests that these investments are not yet generating positive returns. Risk factors for Stratec SE include a medium liquidity risk, as indicated by the negative net cash position after subtracting total debt. The company's dilution risk is assessed as low, which suggests that there is little immediate threat to shareholder value from new share issuances. The risk assessment also notes that the company's liquidity position is a key concern, as it may affect its ability to meet short-term obligations. Recent events related to Stratec SE include analyst estimates that provide a mean price target of 30.62 EUR and a median price target of 30.50 EUR. The mean recommendation from analysts is 2.14, which is slightly above a "buy" rating. These estimates suggest that analysts have a generally positive outlook on the company's stock, although there is a range of opinions, with some analysts recommending a strong buy and others a hold.